Conversion to Sirolimus in Posttransplant Renal Neoplasms

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2264-2266

  Lopez, V ^a   Gutierrez, C ^a   Cabello, M ^a   Burgos, D ^a   Sola, E ^a   Gonzalez Molina, M ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DOSE RESPONSE; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; MALE; MORTALITY; MOUTH ULCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CALCINEURIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TIME FACTORS;

EID: 34548701090     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.055     Document Type: Article

References (12)

1. Sanchez-Fructuoso A., Conesa J., and Perez Flores I. Conversion to sirolimus in renal transplant patients with tumors. Transplant Proc 38 (2006) 2451
2. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S
3. Lee V., and Chapman J. Sirolimus: its role in nephrology. Nephrology 10 (2005) 606
4. Kochl G.E., Andrassy J., Guba M., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77 (2004) 1319
5. Luan F.L., Hojo M., Maluccio M., et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565
6. Zmonarski S.C., Boratynska M., and Rabzynski J. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37 (2005) 964
7. Stallone G., Shena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317
8. Gutierrez-Dalmau A., Sanchez-Fructuoso A., Sanz-Guajardo A., et al. Efficacy of conversion to sirolimus in post-transplantation Kaposi's sarcoma. Transplant Proc 37 (2005) 3836
9. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 23 (2000) 101
10. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 15 (2005) S254
11. Luan F.L., Ding R., Sharma V.K., et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63 (2003) 917
12. Nepomuceno R.R., Balatoni C.E., Natkunam Y., et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63 (2003) 4472